Chalcogen Bonded Directly To Ring Carbon Of The Hetero Ring Patents (Class 514/455)
-
Publication number: 20150030551Abstract: Provided are benzopyran compounds of formula I, for example, pomiferin-3?,4?-dimethyl ether, and the use of such compounds and compositions thereof to modulate (e.g., inhibit) melanogenesis and pigmentation. wherein R3, R4, R5, R6, R7 and R8 are described herein. Also provided are plant extracts containing a compound of formula I, and the use of such a plant extract to modulate (e.g., inhibit) melanogenesis and pigmentation. The compound or plant extract may be prepared as pharmaceutical and cosmetic compositions, and may be used for the prevention and treatment of conditions that are related to aberrant melanogenesis activity.Type: ApplicationFiled: August 12, 2014Publication date: January 29, 2015Inventor: Seth J. ORLOW
-
Publication number: 20150024055Abstract: The present invention provides enhanced immediate release formulations of topiramate, in which 80% of the active ingredient is released in the period of time of not more than 30 min. These formulations may be advantageously used for the treatment of acute neurological conditions, such as migraine.Type: ApplicationFiled: October 6, 2014Publication date: January 22, 2015Applicant: Supernus Pharmaceuticals, Inc.Inventors: Likan Liang, Padmanabh P. BHATT, Hua WANG
-
Patent number: 8933116Abstract: Disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the compound of Formula (I) and use of the compound in the treatment of neurodegenerative diseases or conditions such as Alzheimer's disease.Type: GrantFiled: April 4, 2012Date of Patent: January 13, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Wen-Lian Wu, Duane A. Burnett, William J. Greenlee
-
Publication number: 20150005373Abstract: The use, as a dermatological or cosmetic medicament, of compounds capable of transiently interacting with the AhR receptor (aryl hydrocarbon receptor) as agents for modulating skin functions such as sebaceous function, skin healing, skin atrophy termed “dermatoporosis”, estrogen deprivation and defense against infection, without inducing other toxic effects of the TCDD type. The compounds that interact with the AhR receptor are chosen in that they have a metabolism favorable to the dissociation of these effects, in particular by virtue of in situ production from a precursor and/or metabolization modulated in situ.Type: ApplicationFiled: July 30, 2014Publication date: January 1, 2015Inventor: Jean Hilaire Saurat
-
Publication number: 20140377382Abstract: The invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration. In particular, the invention relates to use of one or more cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration, wherein the one or more cannabinoid-containing plant extracts comprise: i) a cannabinoid-containing fraction; and ii) a non-cannabinoid containing fraction.Type: ApplicationFiled: January 24, 2014Publication date: December 25, 2014Applicant: GW Pharma LimitedInventors: Geoffrey Guy, Bettina Platt
-
Publication number: 20140349919Abstract: The present invention relates to certain chromane-like cyclic prenylflavonoids, in particular the compounds of formulae (I), (II) and (III) as described and defined herein, for use in the treatment or prevention of a neurological disorder, as well as their use in promoting neuronal differentiation, neurite outgrowth and neuroprotection.Type: ApplicationFiled: June 15, 2012Publication date: November 27, 2014Inventors: Ludwig Aigner, Eleni Oberbauer-Hofmann, Sébastien Couillard-Despres, Francisco Javier Rivera, Herbert Riepl, Corinna Urmann, Martin Biendl
-
Publication number: 20140350093Abstract: Disclosed are methods of treating an animal for insulin resistance and associated diseases or conditions, activating the transcriptional activity of heat shock factor 1 (HSF1), or inducing the expression of heat shock protein 70 (HSP70) in an animal in need thereof, wherein the methods involve administering an effective amount of one or more compounds of formula (I) or an epimer thereof, wherein Ar, and R1-R6 are described herein. Examples of diseases or conditions associated with insulin resistance include diabetes, obesity, inflammation, metabolic syndrome, polycystic ovary disease, arteriosclerosis, non-alcoholic fatty liver disease, reproductive abnormality in a female, and growth abnormality.Type: ApplicationFiled: January 3, 2013Publication date: November 27, 2014Inventors: Leonard M. Neckers, Carole A.C. Sourbier, W. Marston Linehan, Jane B. Neckers, Min-Jung Lee, Bradley T. Scroggins, John A. Beutler
-
Publication number: 20140349918Abstract: The present invention relates to xanthone analogs. Such compounds may be used in the treatment of bacterial infections.Type: ApplicationFiled: September 10, 2012Publication date: November 27, 2014Applicants: Singapore Health Services Pte Ltd., Agency for Science, Technology and ResearchInventors: Hanxun Zou, Lakshminiarayan Rajanmani, Lei Zhou, Chang Chui Charles Tang, Jun Jie Koh, Tiang Hwee Donald Tan, Chandra Verma, Roger W. Beuerman, Shouping Liu, Saraswathi Padmanabhan
-
Patent number: 8895058Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.Type: GrantFiled: October 8, 2013Date of Patent: November 25, 2014Assignee: Vivus, Inc.Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
-
Patent number: 8895057Abstract: The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.Type: GrantFiled: October 8, 2013Date of Patent: November 25, 2014Assignee: Vivus, Inc.Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
-
Publication number: 20140341845Abstract: Methods for the treatment of a cell proliferation disorder in a subject, involving: (1) administering to the subject at least one activatable pharmaceutical agent that is capable of effecting a predetermined cellular change when activated, either alone or in combination with at least one energy modulation agent; and (2) applying an initiation energy from an initiation energy source to the subject, wherein the applying activates the activatable agent in situ, thus causing the predetermined cellular change to occur, wherein the predetermined cellular change treats the cell proliferation disorder, preferably by causing an increase or decrease in rate of cell proliferation, and a kit for performing the method, a computer implemented system for performing the method, a pharmaceutical composition useful in the method and a method for causing an autovaccine effect in a subject using the method.Type: ApplicationFiled: August 4, 2014Publication date: November 20, 2014Applicant: lmmunolight, LLC.Inventor: Frederic A. BOURKE, JR.
-
Publication number: 20140322136Abstract: The present invention provides methods to reduce or inhibit weight gain by administering inhibitors of the SirT1 protein to a subject. Methods to identify such inhibitors are also disclosed.Type: ApplicationFiled: May 6, 2014Publication date: October 30, 2014Inventors: Yansong GU, Hongzhe LI
-
Publication number: 20140315992Abstract: Compositions and methods for the detection and treatment of autism and autistic spectrum disorder are provided.Type: ApplicationFiled: July 9, 2012Publication date: October 23, 2014Applicant: The Children's Hospital of PhiladelphiaInventors: Hakon Hakonarson, Dexter Hadley, Zhi-Liang Wu, Joseph Glessner
-
Publication number: 20140314740Abstract: The invention provides compositions and methods for the prevention, amelioration, and/or treatment of diabetes complications, including ocular diseases associated with increased glucose transport and/or oxidative stress.Type: ApplicationFiled: December 10, 2012Publication date: October 23, 2014Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Peter A. Campochiaro, Lili Lu
-
Patent number: 8865762Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of bone diseases comprising colforsin daropate, and more particularly, the present invention relates to a pharmaceutical composition for the prevention or treatment of bone diseases such as bone fracture and osteoporosis, which inhibits osteoclast differentiation and bone resorption caused by osteoclasts and promotes osteoblast differentiation and the activity of osteoblasts, and a health functional food composition comprising colforsin daropate.Type: GrantFiled: July 16, 2010Date of Patent: October 21, 2014Assignees: Korea Research Institute of Bioscience and Biotechnology, Korea Research Institute of Chemical TechnologyInventors: Byoung Mog Kwon, Dong Cho Han, Myung Ae Bae, Seong Hwan Kim, Yong Ki Min
-
Publication number: 20140308342Abstract: The present invention relates to chimeric (preferably, bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds preferably covalently bind to the urokinase receptor and recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and/or antibody-dependent cellular cytotoxicity (ADCC) against a large number and variety of cancers, thus providing cancer cell death and/or an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.Type: ApplicationFiled: November 7, 2012Publication date: October 16, 2014Inventors: David A. Spiegel, Charles E. Jakobsche
-
Publication number: 20140302148Abstract: The present invention provides stable, fast-acting liposomal and micelle formulations of cannabinoids that are suitable for pharmaceutical and nutraceutical applications.Type: ApplicationFiled: June 23, 2014Publication date: October 9, 2014Inventor: Robert WINNICKI
-
Publication number: 20140303243Abstract: Compositions and methods for the detection and treatment of autism and autistic spectrum disorder are provided.Type: ApplicationFiled: May 30, 2014Publication date: October 9, 2014Inventors: Hakon Hakonarson, Tara Wenger, Charlly Kao, Dexter Hadley, Zhi-liang Wu, Joseph Glessner
-
Patent number: 8853261Abstract: Pharmaceutical, cosmetic, nutraceutical and dietary compositions derived from Garcinia mangostana are rich in ?-mangostin and other demethylated xanthones. These compositions exhibit potent antioxidative activity and reduce inflammation. These compositions may be used in a method of treating TNF-?, and aP2 mediated disorders. The compositions are prepared by subjecting a hydroalcoholic extract of fruit pericarp (fruit hull) of Garcinia mangostana, wherein said hydroalcoholic extract comprises predominantly ?-mangostin, to demethylation in the presence of a Lewis acid, an organic base and a catalyst.Type: GrantFiled: January 21, 2008Date of Patent: October 7, 2014Assignee: Laila NutraceuticalsInventors: Ganga Raju Gokaraju, Rama Raju Gokaraju, Trimurtulu Golakoti, Venkateswara Rao Chirravuri, Kiran Bhupathiraju
-
Publication number: 20140294950Abstract: The disclosed embodiments relate to, dosing regimens for the administration of topiramate, optionally in combination with one or more sympathomimetic agents such as phentermine. The dosing regimens can, for example, limit the exposure of subjects to topiramate, identify subjects who are unlikely to obtain a benefit from treatment with escalating dosages of topiramate (with or without the sympathomimetic agent, such as phentermine), or both, thereby reducing or eliminating harmful or intolerable side effects in subjects who are unlikely to respond to treatment and maximizing the therapeutic benefits from treatment in subjects who do respond.Type: ApplicationFiled: March 17, 2014Publication date: October 2, 2014Inventors: Peter TAM, Roman DVORAK, Craig PETERSON
-
Patent number: 8846742Abstract: The present invention relates to compounds that may be used to inhibit activation of protein kinase G (“PKG”). It is based, at least in part, on the discovery of the tertiary structure of PKG and the identification of molecules that either bind to the active site of PKG and/or are analogs of balanol.Type: GrantFiled: February 14, 2007Date of Patent: September 30, 2014Assignee: The Trustees of Columbia University in the City of New YorkInventors: Richard Ambron, Ying-Ju Sung, Jeremy Greenwood, Leah Frye, Shi-Xian Deng, Yuli Xie, Donald W. Landry
-
Publication number: 20140286938Abstract: The present invention relates to spiroketal compounds that are useful in methods of treating or preventing protozoal infections, parasitic infections, bacterial infections, cell proliferative disorders and anti inflammatory disorders. The spiroketal compounds are also useful as immunosuppressive agents, and also in methods of controlling pests.Type: ApplicationFiled: March 21, 2014Publication date: September 25, 2014Applicant: EcoBiotics LtdInventors: Paul Warren Reddell, Victoria Anne Gordon
-
Patent number: 8835448Abstract: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., Syndrome X), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type II diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence.Type: GrantFiled: November 30, 2012Date of Patent: September 16, 2014Assignee: Melior Pharmaceuticals I, Inc.Inventors: Andrew G. Reaume, Michael S. Saporito
-
Publication number: 20140243396Abstract: Imidazoquinolines, as set forth in formula (I), are useful for inhibiting growth or proliferation of mucoepidermoid carcinoma cells. The therapeutic and prophylactic treatments provided by this invention are practiced by administering to a patient in need thereof an amount of a compound of formula (I) that is effective to inhibit growth or proliferation of the mucoepidermoid carcinoma cells.Type: ApplicationFiled: September 27, 2012Publication date: August 28, 2014Inventors: James D. Griffin, Lizi Wu, Jie Chen
-
Patent number: 8802636Abstract: The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.Type: GrantFiled: January 6, 2010Date of Patent: August 12, 2014Assignee: Vivus, Inc.Inventor: Thomas Najarian
-
Publication number: 20140221470Abstract: A compound for inhibiting activity of glutathione s-transferase omega 1 is provided and is represented by the following Formula 1: in which A is p-quino, and R is selected from the group consisting of the following Formula 1a and Formula 1b, where n in Formula 1 is 1 or 2, m in Formula 1b is 1 or 2, and n? in Formula 1b is 1, 2, or 3:Type: ApplicationFiled: March 18, 2013Publication date: August 7, 2014Applicant: CHINA MEDICAL UNIVERSITYInventors: Yang-Chang WU, Kuo-Hsiung LEE, Fang-Rong CHANG, Da-Wei CHUANG, Juan-Cheng YANG
-
Publication number: 20140221471Abstract: Described herein are compositions and methods for preventing and/or treating skin diseases including, but not limited to, psoriasis and atopic dermatitis as well as providing anti-aging benefits which results in reduced appearance of wrinkles and aged skin, improved skin color, treatment of photodamaged skin, improvement in skin's radiance and clarity and finish, and an overall healthy and youthful appearance of the skin, involving aberrant angiogenesis and hyperplasia employing one or more benzo[c]chromen-6-one derivatives.Type: ApplicationFiled: February 3, 2014Publication date: August 7, 2014Inventor: David Sherris
-
Publication number: 20140221468Abstract: Store operated calcium channel modulating compounds, and methods for using the same, are provided. These compounds and methods find use in a variety of applications in which modulation of store operated calcium channels is desired.Type: ApplicationFiled: December 9, 2011Publication date: August 7, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Chan Young Park, Amir M. Sadaghiani, Ricardo Ei Dolmetsch
-
Publication number: 20140200265Abstract: This invention relates to the use of a natural compound from natural sources for its therapeutic uses. More particularly, it relates to a compound 1,3,5,7-tetrahydroxy-8-isoprenylxanthone (TI, FIG. 1), that is naturally occurring in the plant of Garcinia esculenta Y. H. Li, and its biological activity of inhibiting nitric oxide production and microRNA 155 expression in stimulated macrophages, which can be developed as potential anti-inflammatory drugs.Type: ApplicationFiled: January 8, 2014Publication date: July 17, 2014Applicant: Hong Kong Baptist UniversityInventors: Hongxi Xu, Dandan Zhang, Hong Zhang, Kaixian Chen, Zhaoxiang Bian, Chengyuan Lin, Dajian Yang, Shilin Chen, Aiping Lu, Albert Sun Chi Chan
-
Publication number: 20140199291Abstract: The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.Type: ApplicationFiled: September 13, 2008Publication date: July 17, 2014Applicant: Biogen Idec MA IncInventors: Leonid Gorelik, Margot Brickelmaier, Alexey Lugovskoy
-
Patent number: 8778914Abstract: The present invention relates to a prodrug, comprising a pharmaceutically and/or diagnostically active compound, and one or more bisphosphonate groups, to a process for producing such a prodrug, and to a pharmaceutical composition comprising said prodrug, to be used for the treatment of bone-related disorders such as bone cancer.Type: GrantFiled: August 24, 2010Date of Patent: July 15, 2014Assignee: KTB Tumorforschungsgesellschaft mbHInventors: Felix Kratz, Katrin Hochdoerffer
-
Publication number: 20140187623Abstract: The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.Type: ApplicationFiled: October 8, 2013Publication date: July 3, 2014Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
-
Publication number: 20140186328Abstract: The present invention provides neuroprotective polyphenol compounds, which can be synthetic analogs of fisetin, baicalein or chlorogenic acid, that maintain neuroprotective, anti-inflammatory, glutathione promoting, and/or antioxidant properties. The neuroprotective polyphenol compounds are useful for promoting, enhancing and/or increasing neuron protection, growth and/or regeneration. The polyphenol compounds further find use for increasing and or maintaining intracellular glutathione (GSH) levels. The polyphenol compounds are also useful for treating, preventing, mitigating and/or delaying neurodegenerative conditions, including diabetes, Parkinson's disease, Huntington's disease, Alzheimer's disease, non-Alzheimer's dementias, multiple sclerosis, traumatic brain injury, spinal cord injury or ALS.Type: ApplicationFiled: February 5, 2014Publication date: July 3, 2014Applicant: Salk Institute for Biological StudiesInventors: David R. Schubert, Pamela A. Maher, Chandramouli Chiruta
-
Publication number: 20140186329Abstract: The present invention provides methods of use of polyphenol compounds for treating, preventing, mitigating and delaying ischemia or a condition where ischemia occurs. In one embodiment, the method comprises providing a polyphenol analog; and administering the polyphenol analog to a subject to treat ischemia or a condition where ischemia occurs. Various embodiments of the present invention are useful for the treatment of patients having, or at risk for, any of (1) ischemic stroke, (2) hemorrhagic stroke, (3) cardiovascular disease, (4) ischemia related spinal cord injury, (5) ischemia in diabetic patients, or (6) embolic stroke. For example, use of the polyphenol compounds can maintain glutathione levels in the patient.Type: ApplicationFiled: February 6, 2014Publication date: July 3, 2014Inventors: Paul A. Lapchak, David R. Schubert, Pamela A. Maher, Chandramouli Chiruta
-
Patent number: 8765719Abstract: An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a prodrug thereof, wherein R1 is H, OH, an alkoxy group, an acyl group, or a thioacyl group, R2 is an acyl group, a thioacyl group, CONR7R8, or CSNR7R8 (R7 and R8 being each independently H, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group), or R1 and R2 together may form a ring, X1 and X2 may be the same or different and are each —CR3R4—, —SiR3R4— or oxygen, and R3 and R4 may be the same or different and are each an alkyl group containing 1 to 6 carbon atoms.Type: GrantFiled: August 20, 2009Date of Patent: July 1, 2014Assignee: Kagoshima UniversityInventors: Masanori Baba, Yuichi Hashimoto
-
Publication number: 20140171455Abstract: Methods for deterring microglia-mediated neurotoxicity in a human or non-human animal subjects comprising the step of inhibiting or blocking the intermediate-conductance calcium-activated potassium channel Kv1.3 in microglia, such as in subjects how suffer from neurodegenerative diseases (e.g., Alzheimer's Disease) or ischemic/anoxic/hypoxic conditions. The inhibition or blocking of the KCa1.3 channels may be accomplished by administering a substance that inhibits Kv1.3 in microglia. Examples of Kv1.3 inhibiting substances include certain 5-phenoxyalkoxypsoralens, such as (4-Phenoxybutoxy)psoralen (PAP-1) as well as certain 4-phenoxybutoxy-substituted heterocyclic compounds.Type: ApplicationFiled: June 8, 2012Publication date: June 19, 2014Applicant: The Regents of the University of CaliforniaInventors: Heike Wulff, Lee-Way Jin, Izumi Meezawa
-
Publication number: 20140161720Abstract: Described herein are methods and compositions comprising a compound of formula (I), e.g., dehydro-alpha-lapachone, or an analog, derivative, isomer, prodrug, or pharmaceutically acceptable salt thereof, for treatment and/or prevention of angiogenic- or vascular-associated diseases or disorders. The compound has anti-vascular activity. In some embodiments, the compound has anti-vascular activity that targets pathways other than VEGF pathways. In some embodiments, the compound or the composition further comprises anti-tumor activity. In some embodiments, the compound or the composition can decrease adhesion or motility of at least one cell (e.g., endothelial cells or cancer cells).Type: ApplicationFiled: May 25, 2012Publication date: June 12, 2014Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Igor Garkavtsev, Rakesh K. Jain
-
Publication number: 20140148383Abstract: Obesity is inhibited by administering to a person in need thereof an effective amount of entacapone ((2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide), or a pharmaceutically-acceptable salt thereof, particularly in conjunction with a second, different anti-obesity medicament. Pharmaceutical compositions comprise entacapone copackaged or coformulated with a second, different anti-obesity medicament.Type: ApplicationFiled: January 4, 2014Publication date: May 29, 2014Applicant: NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJINGInventors: Niu Huang, Gang Zhi, Jijie Chai, Shiming Peng, Nannan Hou
-
Patent number: 8722700Abstract: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.Type: GrantFiled: May 13, 2013Date of Patent: May 13, 2014Assignee: Wyeth LLCInventors: Joseph T. Rubino, Victoria Siskavich, Maureen M. Harrison, Pooja Gandhi
-
Patent number: 8722085Abstract: Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.Type: GrantFiled: July 16, 2010Date of Patent: May 13, 2014Assignee: Orexigen Therapeutics, Inc.Inventors: Anthony McKinney, Gary Tollefson, Eckard Weber, Rick Soltero
-
Patent number: 8716486Abstract: Methods of treating or suppressing oxidative stress disorders including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2-heterocyclylaminoalkyl-(p-quinone) derivatives.Type: GrantFiled: June 23, 2009Date of Patent: May 6, 2014Assignee: Edison Pharmaceuticals, Inc.Inventors: Andrew W. Hinman, Orion D. Jankowski, Kieron E. Wesson
-
Publication number: 20140105920Abstract: Described herein are compositions and methods for preventing and/or treating diseases involving aberrant angiogenesis employing one or more benzo[c]chromen-6-one derivatives.Type: ApplicationFiled: May 23, 2013Publication date: April 17, 2014Inventor: David Sherris
-
Publication number: 20140100270Abstract: Methods and compositions for reducing radiation damage in a subject with analog or derivative of benzo[c]chromen-6-one.Type: ApplicationFiled: February 16, 2012Publication date: April 10, 2014Inventor: David I. Sherris
-
Patent number: 8691281Abstract: The present invention relates to a solid pharmaceutical composition including the active principle 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate. The present invention also relates to polymorphs of the 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate compound.Type: GrantFiled: March 26, 2012Date of Patent: April 8, 2014Assignee: Ipsen Pharma S.A.S.Inventors: Delphine Delahaye, Christian Diolez, Alain Rolland, Francis Diancourt, Gérard Coquerel, Damien Martins, Barry Victor Lloyd Potter, Lok Wai Lawrence Woo
-
Publication number: 20140080903Abstract: The invention discloses a new use of ?-Mangostin in medicine, which is application of ?-Mangostin in preparation of medicaments for Alzheimer's disease. Under the new working concentration, ?-Mangostin showed the capability to inhibit the aggregation and deposition of A?. Moreover, it displayed the neuroprotective effect against neurotoxicity caused by A? oligomer, which maintained normal morphology of mammalian neuron cells, enhanced their normal physiological function, and realized the intervention in pathological process of Alzheimer's disease. The invention provided a new approach to treat Alzheimer's disease.Type: ApplicationFiled: February 14, 2012Publication date: March 20, 2014Applicant: BOMAI LIMITEDInventor: Zheng Xia
-
Patent number: 8664411Abstract: Disclosed are novel gamma secretase inhibitors of the formula. Also disclosed are methods of inhibiting gamma-secretase, methods of treating neurodegenerative diseases, and methods of treating Alzheimer's Disease. Also disclosed are processes for preparing alkenes in one reaction step using a mixture of an aldehyde (or ketone) and an alkyl substituted with two electron withdrawing groups, and reacting the mixture with: (a) a sulfonyl halide (e.g., a sulfonyl chloride) and a basic tertiary amine, or, (b) a sulfonyl anhydride and a basic amine, or (c) an aryl-C(O)-halide and a basic tertiary amine, or (d) an aryl-C(O)—O—C(O)-aryl and a basic tertiary amine, or (e) an heteroaryl-C(O)-halide and a basic tertiary amine, or (f) a heteroaryl-C(O)—O—C(O)-heteroaryl and a basic tertiary amine.Type: GrantFiled: July 1, 2008Date of Patent: March 4, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Wen-Lian Wu, Thomas A. Bara, Duane A. Burnett, John W. Clader, Martin S. Domalski, Yan Jin, Hubert B. Josien, Hongmei Li, Xian Liang, Dmitri A. Pissarnitski, Thavalakulamgara K. Sasikumar, Jesse K. Wong, Ruo Xu, Zhiqiang Zhao, Paul McNamara
-
Publication number: 20140056977Abstract: The present invention relates to a solid pharmaceutical composition including the active principle 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate. The present invention also relates to polymorphs of the 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate compound.Type: ApplicationFiled: August 1, 2013Publication date: February 27, 2014Applicant: Ipsen Pharma S.A.S.Inventors: Nathalie MONDOLY, Bertrand Poirot, Anne Brochard, Joël Richard, Delphine Delahaye, Christian Diolez, Alain Rolland, Francis Diancourt, Gérard Coquerel, Damien Martins, Julie Linol, Ophélie Houssin, Marie-Noêlle Petit, Barry, Victor, Lloyd Potter, Lok, Wai Lawrence Woo
-
Publication number: 20140057950Abstract: The present invention relates to compounds of the general formula (I) which show a specific activity against cancer cell lines, the use of these compounds for prophylaxis and treatment of cancer as well as to pharmaceutical compositions containing at least one compound of general formula (I).Type: ApplicationFiled: December 22, 2011Publication date: February 27, 2014Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DE WISSENSCHAFTEN E.V.Inventors: Mathias Christmann, Lea Radtke, Herbert Waldmann, Matthieu Willot, Slava Ziegler, Hongyan Sun
-
Patent number: 8648112Abstract: The subject invention is drawn to ellagitannin metabolites (e.g., urolithin) that find use in treating or preventing a neoplastic disease in a subject.Type: GrantFiled: April 20, 2012Date of Patent: February 11, 2014Assignee: The Regents of the University of CaliforniaInventors: Navindra P. Seeram, David Heber
-
Publication number: 20140039010Abstract: Disclosed are a method for treating an aging-related disease and a method for screening a therapeutic agent for an aging-related disease. The method for treating an aging-related disease includes administering to a subject a progerin expression inhibitor as an active ingredient. The method for screening a therapeutic agent for an aging-related disease includes selecting a candidate drug inhibitory of progerin expression.Type: ApplicationFiled: March 19, 2012Publication date: February 6, 2014Applicant: Pusan National University Industry-University Cooperation FoundationInventors: Bum Joon Park, Nam Chul Ha, Gyu Yong Song, Ji Hyun Lee, Su Jin Lee, Youn Sang Jung